$TBPH insider trading
Over the last 12 months, Theravance Biopharma insiders reported no purchases and 19 sales totaling $9.0M across SEC Form 4 filings. 32% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $9.0M 19 events
- Events · 12m
- 19 Form 4 filings, grouped
- Insiders · 12m
- 12 distinct reporters
- 10b5-1 share
- 32% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | PAKIANATHAN DEEPIKAD | ▽ Sale to issuer | 64,074 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | O'Connor DonalD | ▽ Sale to issuer | 80,213 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | MITCHELL DEAN JD | ▽ Sale to issuer | 97,213 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | GRAY SUSANNAHD | ▽ Sale to issuer | 48,146 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | Smaldone Alsup LaurieD | ▽ Sale to issuer | 80,989 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER · O·D | ▽ Sale to issuer | 115,967 | — | — | -100% | 2 tranches · indirect |
| Sep 23, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER · O·D | ▽ Sale to issuer | 1,611,022 | — | — | -100% | 3 tranches |
| Sep 23, 2026 | Sawaf AzizSVP & CHIEF FINANCIAL OFFICER · O | ▽ Sale to issuer | 336,841 | — | — | -100% | 3 tranches |
| Sep 23, 2026 | Miller AineSVP, DEV & HEAD OF IRE OFFICE · O | ▽ Sale to issuer | 189,826 | — | — | -100% | 2 tranches |
| Sep 23, 2026 | Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY · O | ▽ Sale to issuer | 355,168 | — | — | -100% | 3 tranches |
| Sep 23, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▽ Sale to issuer | 213,476 | — | — | -100% | 2 tranches |
| Sep 15, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▼ Sale | 13,314 | $17.03 | $227K | -5.9% | plan · 3 tranches |
| Jul 7, 2026 | Samaha Eli10% | ▼ Sale | 6,964 | $17.14 | $119K | -0.1% | 2 tranches · indirect |
| Jul 1, 2026 | Samaha Eli10% | ▼ Sale | 336,697 | $17.2 | $5.8M | -3.5% | 3 tranches · indirect |
| Jun 15, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▼ Sale | 13,314 | $16.39 | $218K | -5.4% | plan · 3 tranches |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▼ Sale | 31,067 | $13.96 | $434K | -11.8% | plan · 3 tranches |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▼ Sale | 31,067 | $18.75 | $583K | -10.1% | plan · 3 tranches |
| Nov 26, 2025 | BROSHY ERAND | ▼ Sale | 29,501 | $20 | $590K | -39.8% | plan · 2 tranches |
| Nov 11, 2025 | BROSHY ERAND | ▼ Sale | 59,000 | $18.11 | $1.1M | -56.1% | plan · 3 tranches |
Every $TBPH filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Theravance Biopharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TBPH feed.